Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumors

23 Apr 2022

Abstract excerpt

OBJECTIVES: Germ cell tumors are highly susceptible to chemotherapy; however, there is a lack of established treatments for consistently relapsing germ cell tumor. Therefore, in this phase II study, we evaluated the efficacy and safety of nivolumab for relapsed germ cell tumor. METHODS: Seventeen adult patients (median age 34 years) with refractory primary germ cell tumor after second-line or higher chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments
Share to Testicular diseases and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35462438
DOI: 10.1111/iju.14885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumorsPMID 35462438Read ↗

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)Semantic proximity Read ↗

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Semantic proximity Read ↗

Targeted therapies for patients with germ cell tumors.Semantic proximity Read ↗

Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targetsSemantic proximity Read ↗

Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumors.Semantic proximity Read ↗

New Anti-Cancer Strategies in Testicular Germ Cell TumorsSemantic proximity Read ↗

Epigenetic treatment combinations to effectively target cisplatin‐resistant germ cell tumors: past, present, and future considerationsSemantic proximity Read ↗

Testicular germ cell tumorsSemantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell TumoursSemantic proximity Read ↗

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.Semantic proximity Read ↗

Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal CounterpartSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.